- CFO James F. Cleary will retire effective June 30, 2026
- Cleary will support the transition in an advisory role through the end of 2026
- Cencora has launched a search for internal and external CFO candidates
- Cleary has served as CFO since 2018 and joined via the MWI Veterinary Supply acquisition
- Company reaffirmed fiscal 2026 adjusted EPS guidance of $17.45–$17.75
- Leadership highlights continuity and strategic stability during transition
Cencora announced that James F. Cleary will retire from his role as Executive Vice President and Chief Financial Officer effective June 30, 2026. The company has initiated an executive search process to identify a successor, considering both internal and external candidates.
Cleary will remain actively involved during the transition, assisting in the search and serving in an advisory capacity through the end of 2026 to support continuity.
Cleary, 62, has served as CFO since November 2018 and joined the company in 2015 following its acquisition of MWI Veterinary Supply, where he previously served as Chief Executive Officer for more than a decade.
Leadership Transition and Legacy
Cencora leadership emphasized Cleary’s impact on the organization, citing his role in driving financial performance, strategic growth, and shareholder value during his tenure as a public company executive.
Robert P. Mauch, President and Chief Executive Officer, noted Cleary’s consistent financial stewardship and leadership. Mark Durcan, Chair of the Board, highlighted his ability to align strategic vision with operational execution.
Cleary stated that his time with the company represents a highlight of his career and expressed confidence in the organization’s future leadership and direction.
Financial Outlook
Alongside the leadership announcement, Cencora reaffirmed its fiscal 2026 adjusted diluted earnings per share guidance in the range of $17.45 to $17.75, signaling continued confidence in its financial performance and outlook.
About Cencora
Cencora is a global pharmaceutical solutions organization focused on improving health outcomes for people and animals. The company partners with pharmaceutical manufacturers and healthcare providers to support access to therapies and ensure reliable delivery of healthcare products.
With more than 51,000 employees worldwide, Cencora is ranked among the top companies on both the Fortune 500 and Global Fortune 500, generating over $300 billion in annual revenue.
Information sourced from the company’s press release.
